Nature Biotechnology
2017-07-12
CRISPR–Cas9 claim sets and the potential to stifle innovation
Benjamin N Gray, W Murray Spruill
Index: 10.1038/nbt.3913
Full Text: HTML
Abstract
Extremely broad claims surrounding Cas9 nucleases have the potential to stifle innovation in the field of genome editing.
Latest Articles:
A wellness study of 108 individuals using personal, dense, dynamic data clouds
2017-07-17
[10.1038/nbt.3870]
Nanoscale imaging of clinical specimens using pathology-optimized expansion microscopy
2017-07-17
[10.1038/nbt.3892]
Wanted: biotech for an aging population
2017-07-12
[10.1038/nbt.3925]
An emerging model for life sciences commercialization
2017-07-12
[10.1038/nbt.3911]
Public biotech in 2016—the numbers
2017-07-12
[10.1038/nbt.3917]